Huang, J., Ma, X., Yang, J., Yang, J., Dong, D. (2026). Early toxicity–driven dose modification and efficacy of adjuvant abemaciclib in high-risk HR+/HER2− early breast cancer: A real-world study in Chinese patients.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.19_suppl.38